Sofosbuvir and Demyelination - a phase IV clinical study of FDA data
Summary:
We study 14,933 people who take Sofosbuvir (sofosbuvir) or have Demyelination. No report of Demyelination is found in people who take Sofosbuvir.
The phase IV clinical study is created by eHealthMe based on reports from the FDA, and is updated regularly.
What is Sofosbuvir?
Sofosbuvir has active ingredients of sofosbuvir. eHealthMe is studying from 9,194 Sofosbuvir users. Check the latest studies of Sofosbuvir.
What is Demyelination?
Demyelination (loss of the myelin covering of some nerve fibres resulting in their impaired function) is found to be associated with 466 drugs and 669 conditions by eHealthMe. Check the latest studies of Demyelination.
No report is found.
Do you take Sofosbuvir and have Demyelination?
- Check whether Demyelination is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, long term effects of, and alternative drugs to Sofosbuvir:
- Sofosbuvir (9,194 reports)
Demyelination treatments and more:
- Demyelination (5,739 reports)
How severe was Demyelination and when was it recovered:
Expand to all the drugs that have ingredients of sofosbuvir:
Browse all side effects of Sofosbuvir:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all the drugs that are associated with Demyelination:
Browse all the conditions that are associated with Demyelination:
How the study uses the data?
The study uses data from the FDA. It is based on sofosbuvir (the active ingredients of Sofosbuvir) and Sofosbuvir (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Pregabalin and Hallucinogen Abuse for Men aged 40-49 - now
- Pregabalin and Illicit Drug Abuse for Men aged 40-49 - now
- Pregabalin and Cocaine Abuse for Men aged 40-49 - a second ago
- Pregabalin and Heroin Abuse for Men aged 40-49 - a second ago
- Pregabalin and Substance Abuse for Men aged 40-49 - a second ago
- Pregabalin and Narcotic Abuse for Men aged 40-49 - 2 seconds ago
- Pregabalin and Drug Abuse for Men aged 40-49 - 4 seconds ago
- Lamotrigine and Conjunctivitis for Women aged 20-29 - 5 seconds ago
- Soma and Aggression for Women aged 50-59 - 5 seconds ago
- Lamotrigine and Inflammation - Conjunctiva for Women aged 20-29 - 5 seconds ago